journal contribution
posted on 2023-03-31, 00:26 authored by Cheng S. Jin, Hironobu Wada, Takashi Anayama, Patrick Z. McVeigh, Hsin Pei Hu, Kentaro Hirohashi, Takahiro Nakajima, Tatsuya Kato, Shaf Keshavjee, David Hwang, Brian C. Wilson, Gang Zheng, Kazuhiro Yasufuku Porphysome-enhanced photothermal therapy in rabbit VX2 lung tumor models.
Funding
Canadian Institutes of Health Research
Ontario Institute for Cancer Research
Natural Sciences and Engineering Research Council of Canada
Canada Foundation for Innovation
History
ARTICLE ABSTRACT
Early detection and efficient treatment modality of early-stage peripheral lung cancer is essential. Current nonsurgical treatments for peripheral lung cancer show critical limitations associated with various complications, requiring alternative minimally invasive therapeutics. Porphysome nanoparticle-enabled fluorescence-guided transbronchial photothermal therapy (PTT) of peripheral lung cancer was developed and demonstrated in preclinical animal models. Systemically administered porphysomes accumulated in lung tumors with significantly enhanced disease-to-normal tissue contrast, as confirmed in three subtypes of orthotopic human lung cancer xenografts (A549, H460, and H520) in mice and in an orthotopic VX2 tumor in rabbits. An in-house prototype fluorescence bronchoscope demonstrated the capability of porphysomes for in vivo imaging of lung tumors in the mucosal/submucosal layers, providing real-time fluorescence guidance for transbronchial PTT. Porphysomes also enhanced the efficacy of transbronchial PTT significantly and resulted in selective and efficient tumor tissue ablation in the rabbit model. A clinically used cylindrical diffuser fiber successfully achieved tumor-specific thermal ablation, showing promising evidence for the clinical translation of this novel platform to impact upon nonsurgical treatment of early-stage peripheral lung cancer. Cancer Res; 76(19); 5870–80. ©2016 AACR.
